Based on this success, researchers are now seeking to identify suitable targets in other hematological malignancies, such as acute myeloid leukemia, multiple myeloma, and even solid tumor like lung cancer, in order to extend the success of the CD19 CAR T-cell therapy (4, 12–15).In this context, although with the success of anti-CD19 chimeric antigen receptor (CAR) T-cells have successfully treated patients with relapsed/refractory (R/R) B-cell leukemia/lymphoma (9–11). Here, CD19 is linked to hematologic disorder.